Fayez Sarofim & Co’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | – | Sell |
-5,571
| Closed | -$303K | – | 283 |
|
|
2022
Q2 | $303K | Hold |
5,571
| – | – | ﹤0.01% | 259 |
|
|
2022
Q1 | $303K | Hold |
5,571
| – | – | ﹤0.01% | 286 |
|
|
2021
Q4 | $307K | Hold |
5,571
| – | – | ﹤0.01% | 297 |
|
|
2021
Q3 | $266K | Hold |
5,571
| – | – | ﹤0.01% | 287 |
|
|
2021
Q2 | $277K | Sell |
5,571
-934
| -14% | -$44.9K | ﹤0.01% | 295 |
|
|
2021
Q1 | $290K | Buy |
+6,505
| New | +$295K | ﹤0.01% | 259 |
|
|
2020
Q1 | – | Sell |
-4,237
| Closed | -$249K | – | 252 |
|
|
2019
Q4 | $249K | Buy |
4,237
+243
| +6% | +$13.5K | ﹤0.01% | 247 |
|
|
2019
Q3 | $213K | Buy |
+3,994
| New | +$205K | ﹤0.01% | 242 |
|
|
2019
Q2 | – | Sell |
-4,145
| Closed | -$217K | – | 256 |
|
|
2019
Q1 | $217K | Buy |
+4,145
| New | +$207K | ﹤0.01% | 237 |
|
|
2018
Q4 | – | Sell |
-4,145
| Closed | -$208K | – | 243 |
|
|
2018
Q3 | $208K | Buy |
+4,145
| New | +$211K | ﹤0.01% | 236 |
|
|
2018
Q2 | – | Sell |
-4,312
| Closed | -$211K | – | 248 |
|
|
2018
Q1 | $211K | Sell |
4,312
-2,240
| -34% | -$104K | ﹤0.01% | 237 |
|
|
2017
Q4 | $290K | Sell |
6,552
-130
| -2% | -$6K | ﹤0.01% | 216 |
|
|
2017
Q3 | $339K | Hold |
6,682
| – | – | ﹤0.01% | 207 |
|
|
2017
Q2 | $360K | Hold |
6,682
| – | – | ﹤0.01% | 203 |
|
|
2017
Q1 | $352K | Sell |
6,682
-328
| -5% | -$16.6K | ﹤0.01% | 207 |
|
|
2016
Q4 | $337K | Hold |
7,010
| – | – | ﹤0.01% | 208 |
|
|
2016
Q3 | $378K | Sell |
7,010
-560
| -7% | -$30.7K | ﹤0.01% | 200 |
|
|
2016
Q2 | $410K | Buy |
7,570
+364
| +5% | +$19.2K | ﹤0.01% | 196 |
|
|
2016
Q1 | $365K | Buy |
7,206
+328
| +5% | +$16.3K | ﹤0.01% | 200 |
|
|
2015
Q4 | $347K | Buy |
6,878
+1,092
| +19% | +$55.7K | ﹤0.01% | 204 |
|
|
2015
Q3 | $278K | Sell |
5,786
-692
| -11% | -$36K | ﹤0.01% | 221 |
|
|
2015
Q2 | $337K | Sell |
6,478
-320
| -5% | -$18K | ﹤0.01% | 208 |
|
|
2015
Q1 | $392K | Buy |
6,798
+480
| +8% | +$27.5K | ﹤0.01% | 193 |
|
|
2014
Q4 | $338K | Hold |
6,318
| – | – | ﹤0.01% | 205 |
|
|
2014
Q3 | $363K | Sell |
6,318
-1,012
| -14% | -$62K | ﹤0.01% | 199 |
|
|
2014
Q2 | $490K | Hold |
7,330
| – | – | ﹤0.01% | 186 |
|
|
2014
Q1 | $490K | Hold |
7,330
| – | – | ﹤0.01% | 181 |
|
|
2013
Q4 | $489K | Buy |
+7,330
| New | +$475K | ﹤0.01% | 181 |
|
|
2013
Q2 | $458K | Buy |
+7,330
| New | +$465K | ﹤0.01% | 176 |
|
Other funds holding GSK
Fayez Sarofim & Co's GSK Position: Q3 2022 in Review
Fayez Sarofim & Co sold out of GSK (GSK) in Q3 2022, closing a stake of 5,571 shares — an estimated $303K sold.
Fayez Sarofim & Co first reported a position in GSK in Q2 2013 and held it in 29 quarters. The position peaked at $490K in Q2 2014. 742 funds tracked by Wall St. Rank hold GSK as of Q3 2022.
- Fayez Sarofim & Co reported no remaining GSK position as of Q3 2022 after selling out during the quarter.
- Fayez Sarofim & Co sold 5,571 GSK shares in Q3 2022, an estimated $303K.
- Fayez Sarofim & Co first reported a position in GSK in Q2 2013 and held it in 29 quarters.
- Fayez Sarofim & Co's GSK position peaked at $490K in Q2 2014.
- 742 funds tracked by Wall St. Rank held GSK as of Q3 2022.
Based on Fayez Sarofim & Co's 13F filing for Q3 2022, filed 15 Nov 2022.